Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy L Comstock

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|May 14, 2010
Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administrationGail Torkildsen, Joel W Proksch, Aron Shapiro, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|June 13, 2015
Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic SolutionPrashant Garg, Umang Mathur, Parul Sony, et al.
Paediatric Drugs|February 2, 2012
Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjectsTimothy L Comstock, Michael R Paterno, Kirk M Bateman, et al.
Current Medical Research and Opinion|June 26, 2008
Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group studyJimmy D Bartlett, Edward J Holland, Dale W Usner, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 10, 2008
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial resultsDavid G Callanan, Glenn J Jaffe, Daniel F Martin, et al.
Cornea|February 5, 2008
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteersEdward J Holland, Jimmy D Bartlett, Michael R Paterno, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 13, 2012
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infectionsBruce E Silverstein, Timothy W Morris, Lynne S Gearinger, et al.
Clinical Therapeutics|March 15, 2011
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenBruce E Silverstein, Catherine Allaire, Kirk M Bateman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 5, 2009
Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJoel W Proksch, Camille P Granvil, Raphaële Siou-Mermet, et al.
Clinical Drug Investigation|March 17, 2012
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and childrenJesse DeLeon, Bruce E Silverstein, Catherine Allaire, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Ophthalmology (Auckland, N.Z.)|May 14, 2010
Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administrationGail Torkildsen, Joel W Proksch, Aron Shapiro, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|June 13, 2015
Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic SolutionPrashant Garg, Umang Mathur, Parul Sony, et al.
Paediatric Drugs|February 2, 2012
Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjectsTimothy L Comstock, Michael R Paterno, Kirk M Bateman, et al.
Current Medical Research and Opinion|June 26, 2008
Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group studyJimmy D Bartlett, Edward J Holland, Dale W Usner, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 10, 2008
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial resultsDavid G Callanan, Glenn J Jaffe, Daniel F Martin, et al.
Cornea|February 5, 2008
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteersEdward J Holland, Jimmy D Bartlett, Michael R Paterno, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 13, 2012
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infectionsBruce E Silverstein, Timothy W Morris, Lynne S Gearinger, et al.
Clinical Therapeutics|March 15, 2011
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenBruce E Silverstein, Catherine Allaire, Kirk M Bateman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 5, 2009
Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJoel W Proksch, Camille P Granvil, Raphaële Siou-Mermet, et al.
Clinical Drug Investigation|March 17, 2012
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and childrenJesse DeLeon, Bruce E Silverstein, Catherine Allaire, et al.
Pageof 4